Read by QxMD icon Read

Prostate v

Krishna B Singh, Eun-Ryeong Hahm, Lora H Rigatti, Daniel P Normolle, Jian-Min Yuan, Shivendra V Singh
We have shown previously that dietary administration of phenethyl isothiocyanate (PEITC), a small molecule from edible cruciferous vegetables, significantly decreases the incidence of poorly-differentiated prostate cancer in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice without any side effects. In this study, we investigated the role of c-Myc-regulated glycolysis in prostate cancer chemoprevention by PEITC. Exposure of LNCaP (androgen-responsive) and 22Rv1 (castration-resistant) human prostate cancer cells to PEITC resulted in suppression of expression as well as transcriptional activity of c-Myc...
March 15, 2018: Cancer Prevention Research
Mark T Corkum, Wei Liu, David A Palma, Glenn S Bauman, Robert E Dinniwell, Andrew Warner, Mark V Mishra, Alexander V Louie
BACKGROUND: Cancer patients frequently search the Internet for treatment options, and hospital websites are seen as reliable sources of knowledge. Guidelines support the use of proton radiotherapy in specific disease sites or on clinical trials. This study aims to evaluate direct-to-consumer advertising content and claims made by proton therapy centre (PTC) websites worldwide. METHODS: Operational PTC websites in English were identified through the Particle Therapy Co-Operative Group website...
March 15, 2018: Radiation Oncology
Junchao Chen, Clara Oromendia, Joshua A Halpern, Karla V Ballman
PURPOSE: Recent years have brought many changes in the management of localized prostate cancer as national screening guidelines have been updated and diagnostic practice patterns evolved. We sought to better understand how the changing landscape influenced treatment utilization in the United States. METHODS: We used the SEER database in this retrospective analysis of patients with clinically localized prostate cancer between 2004 and 2013. We evaluated utilization of primary treatment modalities over time with descriptive and trend analyses, and examined treatment utilization by cancer risk group and age at diagnosis...
March 14, 2018: Prostate
Michael V Fiandalo, John J Stocking, Elena A Pop, John H Wilton, Krystin M Mantione, Yun Li, Kristopher M Attwood, Gissou Azabdaftari, Yue Wu, David S Watt, Elizabeth M Wilson, James L Mohler
Androgen deprivation therapy (ADT) is palliative and prostate cancer (CaP) recurs as lethal castration-recurrent/resistant CaP (CRPC). One mechanism that provides CaP resistance to ADT is primary backdoor androgen metabolism, which uses up to four 3α-oxidoreductases to convert 5α-androstane-3α,17β-diol (DIOL) to dihydrotestosterone (DHT). The goal was to determine whether inhibition of 3α-oxidoreductase activity decreased conversion of DIOL to DHT. Protein sequence analysis showed that the four 3α-oxidoreductases have identical catalytic amino acid residues...
February 16, 2018: Oncotarget
Feng Li, Laura E Pascal, Jianhua Zhou, Yibin Zhou, Ke Wang, Anil V Parwani, Rajiv Dhir, Peng Guo, Dalin He, Joel B Nelson, Zhou Wang
The mechanisms involved in the development of benign prostatic hyperplasia (BPH) are poorly understood. One potential mechanism involved in BPH pathogenesis may involve altered expression of genes related to apoptosis and proliferation because reduced cell death and increased proliferation are thought to contribute to prostatic enlargement. This study examined the expression of B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra large (BCL-XL), two important anti-apoptosis factors that are also capable of inhibiting cell proliferation via accelerated G1 arrest or delayed G1/S transition, using immunostaining in simple prostatectomy BPH specimens from patients naïve to androgen manipulation...
2018: American Journal of Clinical and Experimental Urology
Huimin Lu, Nicholas Bowler, Larry A Harshyne, D Craig Hooper, Shiv Ram Krishn, Senem Kurtoglu, Carmine Fedele, Qin Liu, Hsin-Yao Tang, Andrew V Kossenkov, William K Kelly, Kerith Wang, Rhonda B Kean, Paul H Weinreb, Lei Yu, Anindita Dutta, Paolo Fortina, Adam Ertel, Maria Stanczak, Flemming Forsberg, Dmitry I Gabrilovich, David W Speicher, Dario C Altieri, Lucia R Languino
Therapeutic approaches aimed at curing prostate cancer are only partially successful given the occurrence of highly metastatic resistant phenotypes that frequently develop in response to therapies. Recently, we have described αvβ6, a surface receptor of the integrin family as a novel therapeutic target for prostate cancer; this epithelial-specific molecule is an ideal target since, unlike other integrins, it is found in different types of cancer but not in normal tissues. We describe a novel αvβ6-mediated signaling pathway that has profound effects on the microenvironment...
March 9, 2018: Matrix Biology: Journal of the International Society for Matrix Biology
V Krishnan, N J Patel, J G Mackrell, S A Sweetana, H Bullock, Y L Ma, T H Waterhouse, B C Yaden, J Henck, Q Q Zeng, K Gavardinas, P Jadhav, A Saeed, P Garcia-Losada, D A Robins, C T Benson
We have identified a non-steroidal selective androgen receptor modulator (SARM), termed LY305, that is bioavailable through a transdermal route of administration while highly cleared via hepatic metabolism to limit parent compound exposure in the liver. Selection of this compound and its transdermal formulation was based on the optimization of skin absorption properties using both in vitro and in vivo skin models that supported PBPK modeling for human PK predictions. This molecule is an agonist in perineal muscle while being a weak partial agonist in the androgenic tissues such as prostate...
March 12, 2018: Andrology
Alice F Yan, Yang Wang, Alexander V Ng
Multiple chronic conditions in cancer survivors are highly prevalent and may increase health care costs for both patients and the health care system. Studies of cancer survivors reveal positive effects of physical activity (PA) on reducing risk of cancer recurrence, other chronic conditions, and secondary cancer. Few nationally representative studies have examined how physical activity levels have affected survivors' annual economic burden in the United States. Leisure-time physical activity data from the National Health Interview Survey was linked to health care expenditure data from the Medical Expenditure Panel Survey data (2008-2012)...
March 2018: Preventive Medicine Reports
Niggula Praveen Kumar, Sowjanya Thatikonda, Ramya Tokala, S Sujana Kumari, Uppu Jaya Lakshmi, Chandraiah Godugu, Nagula Shankaraiah, Ahmed Kamal
A facile one-pot method for the synthesis of new phenanthrene fused-dihydrodibenzo-quinolinone derivatives has been successfully accomplished by employing sulfamic acid as catalyst. These new compounds were evaluated for their in vitro cytotoxic potential against human lung (A549), prostate (PC-3 and DU145), breast (MCF-7) and colon (HT-29 and HCT-116) cancer cell lines. Among all the tested compounds, one of the derivatives 8p showed good anti-proliferative activity against A549 lung cancer cell line with an IC50 of 3...
March 1, 2018: Bioorganic & Medicinal Chemistry
Thomas J W Klein Nulent, Matthijs H Valstar, Bart de Keizer, Stefan M Willems, Laura A Smit, Abrahim Al-Mamgani, Ludwig E Smeele, Robert J J van Es, Remco de Bree, Wouter V Vogel
OBJECTIVES: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is used for detection and (re)staging of prostate cancer. However, healthy salivary, seromucous, and lacrimal glands also have high PSMA-ligand uptake. This study aimed to describe physiologic PSMA-ligand uptake distribution characteristics in the head and neck to aid in PSMA PET/CT interpretation and to identify possible new clinical applications for PSMA-ligand imaging. STUDY DESIGN: Thirty consecutive patients who underwent PSMA PET/CT for prostate cancer were evaluated...
January 31, 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Laura E Pascal, Yao Wang, Mingming Zhong, Dan Wang, Anish Bhaswanth Chakka, Zhenyu Yang, Feng Li, Qiong Song, Lora H Rigatti, Srilakshmi Chaparala, Uma Chandran, Anil V Parwani, Zhou Wang
The tumor suppressor genes EAF2 and p53 are frequently dysregulated in prostate cancers. Recently, we reported that concurrent p53 nuclear staining and EAF2 downregulation were associated with high Gleason score. Combined loss of EAF2 and p53 in a murine model induced prostate tumors, and concurrent knockdown of EAF2 and p53 in prostate cancer cells enhanced proliferation and migration, further suggesting that EAF2 and p53 could functionally interact in the suppression of prostate tumorigenesis. Here, RNA-seq analyses identified differentially regulated genes in response to concurrent knockdown of p53 and EAF2...
March 5, 2018: Neoplasia: An International Journal for Oncology Research
Vasudeva Reddy Netala, Suman Bukke, Latha Domdi, S Soneya, Sindhu G Reddy, Murali Satyanarayana Bethu, Venkata Subbaiah Kotakdi, K V Saritha, Vijaya Tartte
The present study reports the biosynthesis of silver nanoparticles (IH-AgNPs) using aqueous leaf extract of Indigofera hisruta L. The biosynthesized IH-AgNPs were found to be FCC crystals, 5-10 nm in size, spherical in shape and stable. The biosynthesized IH-AgNPs showed dose-dependant cytotoxicity against prostate cancer (PC3) (IC50  = 68.5 μg/mL), colon cancer (COLO205) (IC50  = 85.2 μg/mL), and mouse melanoma (B16F10) (IC50  = 80.9 μg/mL). IH-AgNPs were found to be nontoxic towards normal CHO (Chinese hamster ovary) cells...
March 7, 2018: Artificial Cells, Nanomedicine, and Biotechnology
V Piloni, M Bergamasco, G Melara, P Garavello
BACKGROUND: The aim of the present study was to assess the relationship between symptoms of obstructed defecation and findings on magnetic resonance (MR) defecography in males with obstructed defecation syndrome (ODS). METHODS: Thirty-six males with ODS who underwent MR defecography at our institution between March 2013 and February 2016 were asked in a telephone interview about their symptoms and subsequent treatment, either medical or surgical. Patients were divided into 2 groups, one with anismus (Group 1) and one with prolapse without anismus (Group 2)...
March 6, 2018: Techniques in Coloproctology
Megan E V Caram, Jason P Estes, Jennifer J Griggs, Paul Lin, Bhramar Mukherjee
BACKGROUND: Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six "focus drugs" (docetaxel, abiraterone, enzalutamide, sipuleucel-T, radium-223, and cabazitaxel) that have been approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer during the years 2010-2015. We hypothesized that the use of these treatments would vary over time and by region of the country...
March 6, 2018: BMC Cancer
Amar U Kishan, Ryan R Cook, Jay P Ciezki, Ashley E Ross, Mark M Pomerantz, Paul L Nguyen, Talha Shaikh, Phuoc T Tran, Kiri A Sandler, Richard G Stock, Gregory S Merrick, D Jeffrey Demanes, Daniel E Spratt, Eyad I Abu-Isa, Trude B Wedde, Wolfgang Lilleby, Daniel J Krauss, Grace K Shaw, Ridwan Alam, Chandana A Reddy, Andrew J Stephenson, Eric A Klein, Daniel Y Song, Jeffrey J Tosoian, John V Hegde, Sun Mi Yoo, Ryan Fiano, Anthony V D'Amico, Nicholas G Nickols, William J Aronson, Ahmad Sadeghi, Stephen Greco, Curtiland Deville, Todd McNutt, Theodore L DeWeese, Robert E Reiter, Johnathan W Said, Michael L Steinberg, Eric M Horwitz, Patrick A Kupelian, Christopher R King
Importance: The optimal treatment for Gleason score 9-10 prostate cancer is unknown. Objective: To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Design, Setting, and Participants: Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated between 2000 and 2013. Exposures: Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy...
March 6, 2018: JAMA: the Journal of the American Medical Association
Christos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, Elizabeth Bancroft, Emily Vertosick, Tokhir Dadaev, Charles Brendler, Elizabeth Page, Alexander Dias, D Gareth Evans, Jeanette Rothwell, Lovise Maehle, Karol Axcrona, Kate Richardson, Diana Eccles, Thomas Jensen, Palle J Osther, Christi J van Asperen, Hans Vasen, Lambertus A Kiemeney, Janneke Ringelberg, Cezary Cybulski, Dominika Wokolorczyk, Rachel Hart, Wayne Glover, Jimmy Lam, Louise Taylor, Monica Salinas, Lidia Feliubadaló, Rogier Oldenburg, Ruben Cremers, Gerald Verhaegh, Wendy A van Zelst-Stams, Jan C Oosterwijk, Jackie Cook, Derek J Rosario, Saundra S Buys, Tom Conner, Susan Domchek, Jacquelyn Powers, Margreet G E M Ausems, Manuel R Teixeira, Sofia Maia, Louise Izatt, Rita Schmutzler, Kerstin Rhiem, William D Foulkes, Talia Boshari, Rosemarie Davidson, Marielle Ruijs, Apollonia T J M Helderman-van den Enden, Lesley Andrews, Lisa Walker, Katie Snape, Alex Henderson, Irene Jobson, Geoffrey J Lindeman, Annelie Liljegren, Marion Harris, Muriel A Adank, Judy Kirk, Amy Taylor, Rachel Susman, Rakefet Chen-Shtoyerman, Nicholas Pachter, Allan Spigelman, Lucy Side, Janez Zgajnar, Josefina Mora, Carole Brewer, Neus Gadea, Angela F Brady, David Gallagher, Theo van Os, Alan Donaldson, Vigdis Stefansdottir, Julian Barwell, Paul A James, Declan Murphy, Eitan Friedman, Nicola Nicolai, Lynn Greenhalgh, Elias Obeid, Vedang Murthy, Lucia Copakova, John McGrath, Soo-Hwang Teo, Sara Strom, Karin Kast, Daniel A Leongamornlert, Anthony Chamberlain, Jenny Pope, Anna C Newlin, Neil Aaronson, Audrey Ardern-Jones, Chris Bangma, Elena Castro, David Dearnaley, Jorunn Eyfjord, Alison Falconer, Christopher S Foster, Henrik Gronberg, Freddie C Hamdy, Oskar Johannsson, Vincent Khoo, Jan Lubinski, Eli Marie Grindedal, Joanne McKinley, Kylie Shackleton, Anita V Mitra, Clare Moynihan, Gad Rennert, Mohnish Suri, Karen Tricker, Sue Moss, Zsofia Kote-Jarai, Andrew Vickers, Hans Lilja, Brian T Helfand, Rosalind A Eeles
This corrects the article DOI: 10.1038/bjc.2017.429.
March 6, 2018: British Journal of Cancer
P Chandak, N Byrne, H Lynch, C Allen, G Rottenberg, A Chandra, N Raison, H Ahmed, V Kasivisvanathan, O Elhage, P Dasgupta
The surgical management of prostate cancer has been shown to be determined by the anatomical location of the tumour and its associated intricate relationship to the neurovascular bundle and the prostatic capsule. Studies have shown an improvement in decision making about preservation or resection of neurovascular bundles during robotic assisted prostatectomy (RARP) [1,2] during which the surgeon lacks the tactile feedback of conventional open surgery. This article is protected by copyright. All rights reserved...
March 6, 2018: BJU International
Takatsugu Okegawa, Naoki Ninomiya, Kazuki Masuda, Yu Nakamura, Mitsuhiro Tambo, Kikuo Nutahara
OBJECTIVE: We examined whether androgen receptor splice variant 7 (AR-V7) in circulating tumor cell(CTC)clusters can be used to predict survival in patients with bone metastatic castration resistant-prostate cancer (mCRPC) treated with abiraterone or enzalutamide. METHODS: We retrospectively enrolled 98 patients with CRPC on abiraterone or enzalutamide, and investigated the prognostic value of CTC cluster detection (+ v -) and AR-V7 detection (+ v -) using a CTC cluster detection - based AR-V7 mRNA assay...
March 5, 2018: Prostate
Andrea N Burnett-Hartman, Scott V Adams, Aasthaa Bansal, Jean A McDougall, Stacey A Cohen, Andrew Karnopp, Victoria Warren-Mears, Scott D Ramsey
PURPOSE: We aimed to determine whether the association between late-stage cancer and American Indian/Alaska Native (AI/AN) race differed by enrollment in the Indian Health Service Care System (IHSCS). METHODS: We used Surveillance, Epidemiology, and End Results (SEER) data linked to Medicare files to compare the odds of late-stage breast, colorectal, lung, or prostate cancer between non-Hispanic Whites (NHWs) (n=285,993) and AI/ANs with (n=581) and without (n=543) IHSCS enrollment...
2018: Journal of Health Care for the Poor and Underserved
Devi Amujuri, Bandi Siva, B Poornima, Katukuri Sirisha, A V S Sarma, V Lakshma Nayak, Ashok K Tiwari, U Purushotham, K Suresh Babu
A new series of Schizandrin (1) derivatives were synthesized utilizing the C-9 position of the Schizandrin core and evaluated for their cytotoxic activities against HeLa (cervical cancer), A549 (lung cancer), MCF-7 (breast cancer) and DU-145 (prostate cancer) cell lines. Among the synthesized series, 4e, 4f, 4g and 5 showed potent activities against tested cell lines. More significantly, compound 5 exhibited most potent cytotoxic activity against DU-145 with an IC50 value of 1.38 μM which is comparable to the standard agent, doxorubicin...
February 24, 2018: European Journal of Medicinal Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"